Off-target in CML
Nature Chemical Biology
2012년1월30일
The expected benefits from a new kind of drug presently in clinical trials for treatment of chronic myeloid leukemia (CML) is questioned in a study published online this week in Nature Chemical Biology. Formation of the BCR-ABL fusion oncoprotein is the defining molecular event in CML. Inhibition of the activity of this oncoprotein by targeted drugs, such as imatinib, has improved outcomes for patients with CML, but resistance to imatinib can ultimately become a problem. Another important event in CML is the activation of the gene regulatory factor STAT5. In normal and some malignant cell types, STAT5 is activated by the kinase JAK2. Because of this linkage, JAK2 inhibitors have been developed as drugs and are currently in clinical trials for CML. Giulio Superti-Furga, Veronika Sexl and colleagues show that the activity of some of these JAK2 inhibitors is independent of JAK2 expression and likely stems from the inhibition of BCR-ABL. This study suggests that in CML patients that have the BCR-ABL gene fusion, JAK2 may not be the best molecular target.
doi: 10.1038/nchembio.775
리서치 하이라이트
-
7월7일
Public health: Tackling adolescent stressNature
-
6월23일
Scientific community: Women credited less than men in scientific paper authorshipNature
-
5월12일
Geoscience: Monitoring earthquakes at the speed of lightNature
-
5월4일
Microbiology: Bacteriophage therapy helps treat multi-drug resistant infection in an immunocompromised patientNature Communications
-
4월27일
Planetary science: Building blocks of DNA detected in meteoritesNature Communications
-
4월8일
Health: Psilocybin use associated with lower risk of opioid addictionScientific Reports